Aclaris Therapeutics, Inc.
| 17.09.2019, 13:32 (Dieser Beitrag wurde zuletzt bearbeitet: 17.09.2019, 13:50 von Boy Plunger.)
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
https://finance.yahoo.com/news/aclaris-t...jlBzxUKwPj
Aktuell vorbörslich: $1.81 +65%
Übernachthoch: $2.32
![[Bild: chart.ashx?t=ACRS&ty=c&ta=1&p=d&s=l]](https://www.finviz.com/chart.ashx?t=ACRS&ty=c&ta=1&p=d&s=l)
- Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29
- Highly statistically significant results on all secondary efficacy endpoints
- WART-302 is the first of two Phase 3 pivotal trials for the NDA
- If approved, A-101 45% Topical Solution would be the first FDA approved prescription treatment for common warts
https://finance.yahoo.com/news/aclaris-t...jlBzxUKwPj
Aktuell vorbörslich: $1.81 +65%
Übernachthoch: $2.32
__________________
Trading is both, the easiest thing to do and also the most demanding thing you've ever done in your entire life. It can ruin your life, your family, and everything you touch if you don't respect it, or it can change your life, your families, and give you a feeling that is hard to find elsewhere if you succeed.
